Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.

Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.
复制标题

Epigallocatechin-3-gallate 通过直接靶向 PARP16 活性来增强 ER 应激诱导的癌细胞凋亡。

DOI:
10.1038/cddiscovery.2017.34
复制
发表时间:
2017
影响因子:
7
通讯作者:
Wu J
Wu J
中科院分区:
医学2区
文献类型:
--
作者:
Wang J;Zhu C;Song D;Xia R;Yu W;Dang Y;Fei Y;Yu L;Wu J

文献摘要

参考文献

被引文献

相似文献

聚ADP核糖聚合酶(Poly(ADP-ribose)polymerases,PARP)是一种ADP核糖基化酶,在多种细胞过程中发挥重要作用。迄今为止开发的大多数小分子PARP抑制剂都是针对PARP 1(一种聚ADP核糖转移酶)的,并且选择性较差。PARP 16是一种单ADP核糖转移酶,最近已成为一种潜在的治疗靶点,但其抑制剂的开发却落后于人。在这里,我们新的特点表没食子儿茶素-3-没食子酸酯(EGCG)作为PARP 16的潜在抑制剂。我们发现EGCG与PARP 16相关,并在体外显着抑制其活性。此外,EGCG抑制ER应激诱导的PERK磷酸化和未折叠蛋白反应相关基因的转录,导致ER应激条件下的癌细胞凋亡显著增加,这依赖于PARP 16。这些新发现将EGCG作为PARP 16的潜在抑制剂,其可以增强ER应激诱导的癌细胞凋亡,这表明EGCG和ER应激诱导剂的组合可能代表癌症治疗或化学预防的新方法。
Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosylating enzymes and play important roles in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, a poly-ADP-ribose transferase, and suffer from poor selectivity. PARP16, a mono-ADP-ribose transferase, has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Here we newly characterized epigallocatechin-3-gallate (EGCG) as a potential inhibitor of PARP16. We found that EGCG was associated with PARP16 and dramatically inhibited its activity in vitro. Moreover, EGCG suppressed the ER stress-induced phosphorylation of PERK and the transcription of unfolded protein response-related genes, leading to dramatically increase of cancer cells apoptosis under ER stress conditions, which was dependent on PARP16. These findings newly characterized EGCG as a potential inhibitor of PARP16, which can enhance the ER stress-induced cancer cell apoptosis, suggesting that a combination of EGCG and ER stress-induced agents might represent a novel approach for cancer therapy or chemoprevention.
DOI: 10.1021/ac201260c
发表时间: 2011-08-15
影响因子: 7.4
作者:
Fei, Y. Y.;Schmidt, A.;Bylund, G.;Johansson, D. X.;Henriksson, S.;Lebrilla, C.;Solnick, J. V.;Boren, T.;Zhu, X. D.
通讯作者: Zhu, X. D.
DOI: 10.1002/hep.23723
发表时间: 2010-08-01
期刊: HEPATOLOGY
影响因子: 13.5
作者:
Huang, Weixue;Ding, Liya;Yu, Long
通讯作者: Yu, Long
DOI: 10.1063/1.2830286
发表时间: 2008-01-01
影响因子: 1.6
作者:
Fei, Y. Y.;Landry, J. P.;Lam, K. S.
通讯作者: Lam, K. S.
DOI: 10.1038/onc.2012.130
发表时间: 2013-02-14
期刊: ONCOGENE
影响因子: 8
作者:
Luo, B.;Lee, A. S.
通讯作者: Lee, A. S.
DOI: 10.4161/23723556.2014.975089
发表时间: 2015-01
影响因子: 2.1
作者:
Garg AD;Maes H;van Vliet AR;Agostinis P
通讯作者: Agostinis P